Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure that NHSE informs ICBs, practitioners and Regional Pharmacists about amendments to the liothyronine (T3) section in the guidance document entitled Items which should not routinely be prescribed in primary care.

Regional chief pharmacists have been informed of the changes made to the liothyronine section, including Armour Thyroid and liothyronine combination products, of the ‘items that should not be prescribed in primary care’ policy guidance via email. They have been asked to cascade this information through their integrated care board’s regional networks.